Lung, Phase I
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Adriana Kahn, MD
- Anne Chiang, MD, PhD
- Benjamin Y. Lu, MD, PhD
- Carlotta C. Evans, APRN
- Emily Duffield, APRN
- Eric Winer, MD
- Frederick Wilson, MD, PhD
- Gineesha Abraham, APRN
- Ian Krop, MD, PhD
- Jing Du, MD, PhD, MHS
- John Glendening, PA
- Katelyn Scott, APRN
- Kathryn Mason, APRN
- Lajos Pusztai, MD, DPhil
- Marianne Davies, NP, DNP, MSN, APRN, BSN
- Maryam Lustberg, MD, MPH
- Melissa Gambaccini, APRN, AOCNP, FNP-C
- Michael DiGiovanna, MD, PhD
- Michelle Corso, APRN
- Sarah Elizabeth Schellhorn, MD
- Scott Gettinger, MD
- So Yeon Kim, MD
- Last Updated05/20/2026
- Study IRB#2000041727